Emerging Bispecifics in the Treatment Paradigm for R/R LBCL

Expert discusses the emergence of recently approved bispecific antibodies in R/R LBCL, emphasizing the importance of toxicity management for adverse events such as cytokine release syndrome (CRS).

Related Keywords

, Transforming Largeb Cell Lymphoma , Novel Agents , Treatment Paradigm , Dlbcl , Lymphoma , Largeb Cell Lymphoma , Car T , Cart Cell , Cart Cell Therapy , Cart Cell Therapy Lymphoma , Cart Cell Therapy Largeb Lymphoma , Patients With Lbcl , Patients With Largeb Cell Lymphoma , Mechanisms Of Action , Clinical Applications ,